{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:25:03Z","timestamp":1774124703773,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,8]]},"DOI":"10.7759\/cureus.66422","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T09:09:36Z","timestamp":1723108176000},"source":"Crossref","is-referenced-by-count":2,"title":["A Systematic Review on Biomarkers: Are There Reliable Molecular Biomarkers in Patients With Rheumatoid Arthritis-Associated Interstitial Lung Disease?"],"prefix":"10.7759","author":[{"given":"Sheezara  T","family":"Lira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxsuel  R","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u00e9rgila  R","family":"Gon\u00e7alves Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jucier","family":"Gon\u00e7alves Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.11.035","article-title":"Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory","volume":"163","author":"Matson SM","year":"2023","unstructured":"Matson SM, Baqir M, Moua T, et al.. Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory. Chest. 2023, 163:861-9. 10.1016\/j.chest.2022.11.035","journal-title":"Chest"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0011-2021","article-title":"Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management","volume":"30","author":"Kadura S","year":"2021","unstructured":"Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021, 30:210011. 10.1183\/16000617.0011-2021","journal-title":"Eur Respir Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz T","year":"2010","unstructured":"Bongartz T, Nannini C, Medina-Velasquez YF, et al.. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010, 62:1583-91. 10.1002\/art.27405","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2022.2089116","article-title":"Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies","volume":"16","author":"Diesler R","year":"2022","unstructured":"Diesler R, Cottin V. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies. Expert Rev Respir Med. 2022, 16:541-53. 10.1080\/17476348.2022.2089116","journal-title":"Expert Rev Respir Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel253","article-title":"Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis","volume":"46","author":"Young A","year":"2007","unstructured":"Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, Dixey J. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007, 46:350-7. 10.1093\/rheumatology\/kel253","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.11.73","article-title":"Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS\/ERS\/JRS\/ALAT criteria","volume":"11","author":"Yamakawa H","year":"2019","unstructured":"Yamakawa H, Sato S, Tsumiyama E, et al.. Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS\/ERS\/JRS\/ALAT criteria. J Thorac Dis. 2019, 11:5247-57. 10.21037\/jtd.2019.11.73","journal-title":"J Thorac Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease-associated mortality","volume":"183","author":"Olson AL","year":"2011","unstructured":"Olson AL, Swigris JJ, Sprunger DB, et al.. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011, 183:372-8. 10.1164\/rccm.201004-0622OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211138","article-title":"A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality","volume":"76","author":"Hyldgaard C","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, L\u00f8kke A, Bendstrup E, Ellingsen T. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017, 76:1700-6. 10.1136\/annrheumdis-2017-211138","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/h9tc57","article-title":"Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk\/prognostic factors, and treatment landscape","volume":"39","author":"Fazeli MS","year":"2021","unstructured":"Fazeli MS, Khaychuk V, Wittstock K, et al.. Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk\/prognostic factors, and treatment landscape. Clin Exp Rheumatol. 2021, 39:1108-18. 10.55563\/clinexprheumatol\/h9tc57","journal-title":"Clin Exp Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.42640","article-title":"Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease","volume":"75","author":"Koduri G","year":"2023","unstructured":"Koduri G, Solomon JJ. Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2023, 75:2067-77. 10.1002\/art.42640","journal-title":"Arthritis Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103056","article-title":"Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease","volume":"21","author":"Akiyama M","year":"2022","unstructured":"Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev. 2022, 21:103056. 10.1016\/j.autrev.2022.103056","journal-title":"Autoimmun Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2021.28.4.234","article-title":"Association of serum biomarkers with pulmonary involvement of rheumatoid arthritis interstitial lung disease: from KORAIL cohort baseline data","volume":"28","author":"Moon J","year":"2021","unstructured":"Moon J, Lee JS, Yoon YI, et al.. Association of serum biomarkers with pulmonary involvement of rheumatoid arthritis interstitial lung disease: from KORAIL cohort baseline data. J Rheum Dis. 2021, 28:234-41. 10.4078\/jrd.2021.28.4.234","journal-title":"J Rheum Dis"},{"key":"ref13","unstructured":"Study quality assessment tools. (2023). Accessed. July 23, 2024: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1056121","article-title":"Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis","volume":"9","author":"Pulito-Cueto V","year":"2022","unstructured":"Pulito-Cueto V, Remuzgo-Mart\u00ednez S, Genre F, et al.. Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis. Front Mol Biosci. 2022, 9:1056121. 10.3389\/fmolb.2022.1056121","journal-title":"Front Mol Biosci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021275","article-title":"Endothelin-1 as a biomarker of idiopathic pulmonary fibrosis and interstitial lung disease associated with autoimmune diseases","volume":"24","author":"Pulito-Cueto V","year":"2023","unstructured":"Pulito-Cueto V, Genre F, L\u00f3pez-Mej\u00edas R, et al.. Endothelin-1 as a biomarker of idiopathic pulmonary fibrosis and interstitial lung disease associated with autoimmune diseases. Int J Mol Sci. 2023, 24:1275. 10.3390\/ijms24021275","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/art.38904","article-title":"Biomarkers of rheumatoid arthritis-associated interstitial lung disease","volume":"67","author":"Chen J","year":"2015","unstructured":"Chen J, Doyle TJ, Liu Y, et al.. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015, 67:28-38. 10.1002\/art.38904","journal-title":"Arthritis Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201411-1950OC","article-title":"Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers","volume":"191","author":"Doyle TJ","year":"2015","unstructured":"Doyle TJ, Patel AS, Hatabu H, et al.. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015, 191:1403-12. 10.1164\/rccm.201411-1950OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02800-2","article-title":"Identification of biomarkers by machine learning classifiers to assist diagnose rheumatoid arthritis-associated interstitial lung disease","volume":"24","author":"Qin Y","year":"2022","unstructured":"Qin Y, Wang Y, Meng F, Feng M, Zhao X, Gao C, Luo J. Identification of biomarkers by machine learning classifiers to assist diagnose rheumatoid arthritis-associated interstitial lung disease. Arthritis Res Ther. 2022, 24:115. 10.1186\/s13075-022-02800-2","journal-title":"Arthritis Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13474-w","article-title":"Predictors of long-term prognosis in rheumatoid arthritis-related interstitial lung disease","volume":"12","author":"Chen J","year":"2022","unstructured":"Chen J, Chen Y, Liu D, et al.. Predictors of long-term prognosis in rheumatoid arthritis-related interstitial lung disease. Sci Rep. 2022, 12:9469. 10.1038\/s41598-022-13474-w","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex520","article-title":"Anti-citrullinated alpha enolase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis","volume":"57","author":"Alunno A","year":"2018","unstructured":"Alunno A, Bistoni O, Pratesi F, La Paglia GM, Puxeddu I, Migliorini P, Gerli R. Anti-citrullinated alpha enolase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis. Rheumatology (Oxford). 2018, 57:850-5. 10.1093\/rheumatology\/kex520","journal-title":"Rheumatology (Oxford)"},{"key":"ref21","article-title":"Tumour markers in rheumatoid arthritis-associated interstitial lung disease","volume":"34","author":"Wang T","year":"2016","unstructured":"Wang T, Zheng XJ, Ji YL, Liang ZA, Liang BM. Tumour markers in rheumatoid arthritis-associated interstitial lung disease. Clin Exp Rheumatol. 2016, 34:587-91.","journal-title":"Clin Exp Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5606\/ArchRheumatol.2018.6691","article-title":"Tumor-associated antigens in rheumatoid arthritis interstitial lung disease or malignancy?","volume":"33","author":"Sargin G","year":"2018","unstructured":"Sargin G, K\u00f6se R, \u015eent\u00fcrk T. Tumor-associated antigens in rheumatoid arthritis interstitial lung disease or malignancy?. Arch Rheumatol. 2018, 33:431-7. 10.5606\/ArchRheumatol.2018.6691","journal-title":"Arch Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1211790","article-title":"Serum CHI3L1 as a biomarker of interstitial lung disease in rheumatoid arthritis","volume":"14","author":"Yu R","year":"2023","unstructured":"Yu R, Liu X, Deng X, et al.. Serum CHI3L1 as a biomarker of interstitial lung disease in rheumatoid arthritis. Front Immunol. 2023, 14:1211790. 10.3389\/fimmu.2023.1211790","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232978","article-title":"Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease","volume":"15","author":"Avouac J","year":"2020","unstructured":"Avouac J, Cauvet A, Steelandt A, et al.. Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. PLoS One. 2020, 15:e0232978. 10.1371\/journal.pone.0232978","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-022-01661-w","article-title":"Serum uric acid as a diagnostic biomarker for rheumatoid arthritis-associated interstitial lung disease","volume":"45","author":"Wang Z","year":"2022","unstructured":"Wang Z, Wang W, Xiang T, Gong B, Xie J. Serum uric acid as a diagnostic biomarker for rheumatoid arthritis-associated interstitial lung disease. Inflammation. 2022, 45:1800-14. 10.1007\/s10753-022-01661-w","journal-title":"Inflammation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3878-0","article-title":"The serum level and significance of lysyl oxidase-like 2 in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"37","author":"Fu Q","year":"2018","unstructured":"Fu Q, Bai Y, Liu Y, Zhou J, Zheng Y. The serum level and significance of lysyl oxidase-like 2 in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2018, 37:193-8. 10.1007\/s10067-017-3878-0","journal-title":"Clin Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0623-9","article-title":"Fibrocyte measurement in peripheral blood correlates with number of cultured mature fibrocytes in vitro and is a potential biomarker for interstitial lung disease in rheumatoid arthritis","volume":"18","author":"Just SA","year":"2017","unstructured":"Just SA, Lindegaard H, Hejb\u00f8l EK, et al.. Fibrocyte measurement in peripheral blood correlates with number of cultured mature fibrocytes in vitro and is a potential biomarker for interstitial lung disease in rheumatoid arthritis. Respir Res. 2017, 18:141. 10.1186\/s12931-017-0623-9","journal-title":"Respir Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.916583","article-title":"Platelet\/lymphocyte, lymphocyte\/monocyte, and neutrophil\/lymphocyte ratios as biomarkers in patients with rheumatoid arthritis and rheumatoid arthritis-associated interstitial lung disease","volume":"25","author":"Chen Q","year":"2019","unstructured":"Chen Q, Chen DY, Xu XZ, Liu YY, Yin TT, Li D. Platelet\/lymphocyte, lymphocyte\/monocyte, and neutrophil\/lymphocyte ratios as biomarkers in patients with rheumatoid arthritis and rheumatoid arthritis-associated interstitial lung disease. Med Sci Monit. 2019, 25:6474-81. 10.12659\/MSM.916583","journal-title":"Med Sci Monit"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-021-00460-6","article-title":"Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis","volume":"22","author":"Xu L","year":"2021","unstructured":"Xu L, Jiang L, Nie L, Zhang S, Liu L, Du Y, Xue J. Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis. BMC Immunol. 2021, 22:69. 10.1186\/s12865-021-00460-6","journal-title":"BMC Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9124098","article-title":"Endothelial progenitor cells as a potential biomarker in interstitial lung disease associated with rheumatoid arthritis","volume":"9","author":"Pulito-Cueto V","year":"2020","unstructured":"Pulito-Cueto V, Remuzgo-Mart\u00ednez S, Genre F, et al.. Endothelial progenitor cells as a potential biomarker in interstitial lung disease associated with rheumatoid arthritis. J Clin Med. 2020, 9:4098. 10.3390\/jcm9124098","journal-title":"J Clin Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.755268","article-title":"Serum human epididymis protein 4 as a novel biomarker in identifying patients with interstitial lung disease in rheumatoid arthritis","volume":"8","author":"Liang L","year":"2021","unstructured":"Liang L, Chen J, Di C, et al.. Serum human epididymis protein 4 as a novel biomarker in identifying patients with interstitial lung disease in rheumatoid arthritis. Front Med (Lausanne). 2021, 8:755268. 10.3389\/fmed.2021.755268","journal-title":"Front Med (Lausanne)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2021.1879346","article-title":"Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"31","author":"Tanaka N","year":"2021","unstructured":"Tanaka N, Nishimura K, Waki D, Kadoba K, Murabe H, Yokota T. Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2021, 31:1100-6. 10.1080\/14397595.2021.1879346","journal-title":"Mod Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030691","article-title":"Anti-HLA class II antibodies correlate with C-reactive protein levels in patients with rheumatoid arthritis associated with interstitial lung disease","volume":"9","author":"Del Angel-Pablo AD","year":"2020","unstructured":"Del Angel-Pablo AD, Buend\u00eda-Rold\u00e1n I, Mej\u00eda M, P\u00e9rez-Rubio G, Nava-Quiroz KJ, Rojas-Serrano J, Falf\u00e1n-Valencia R. Anti-HLA class II antibodies correlate with C-reactive protein levels in patients with rheumatoid arthritis associated with interstitial lung disease. Cells. 2020, 9:691. 10.3390\/cells9030691","journal-title":"Cells"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105948","article-title":"Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: a monocentric cross-sectional study","volume":"166","author":"Wu X","year":"2020","unstructured":"Wu X, Xu L, Cheng Q, Nie L, Zhang S, Du Y, Xue J. Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: a monocentric cross-sectional study. Respir Med. 2020, 166:105948. 10.1016\/j.rmed.2020.105948","journal-title":"Respir Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(22)00380-0","article-title":"Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case-control study","volume":"5","author":"Kronzer VL","year":"2023","unstructured":"Kronzer VL, Hayashi K, Yoshida K, et al.. Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case-control study. Lancet Rheumatol. 2023, 5:e77-87. 10.1016\/s2665-9913(22)00380-0","journal-title":"Lancet Rheumatol"},{"key":"ref36","article-title":"Prognostic value of plasma levels of IL 13 in patients with rheumatoid arthritis and interstitial lung disease: prospective cohort study","volume":"33","author":"Paulin F","year":"2022","unstructured":"Paulin F, Zamora N, Lombardi D, et al.. Prognostic value of plasma levels of IL 13 in patients with rheumatoid arthritis and interstitial lung disease: prospective cohort study. Rev Argent Reumatol. 2022, 33:215-22.","journal-title":"Rev Argent Reumatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/zy6hbf","article-title":"Human epididymis protein 4 as a new diagnostic biomarker for rheumatoid arthritis-associated interstitial lung disease","volume":"40","author":"Lin T","year":"2022","unstructured":"Lin T, Xu S, Wang Y, Nian X, Shan X, Jiang T, Qiu M. Human epididymis protein 4 as a new diagnostic biomarker for rheumatoid arthritis-associated interstitial lung disease. Clin Exp Rheumatol. 2022, 40:2167-74. 10.55563\/clinexprheumatol\/zy6hbf","journal-title":"Clin Exp Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/3iqvk3","article-title":"Serum sCD25 is an indicator for rheumatoid arthritis-associated interstitial lung disease","volume":"42","author":"Cao S","year":"2024","unstructured":"Cao S, Liu X, Li Y, et al.. Serum sCD25 is an indicator for rheumatoid arthritis-associated interstitial lung disease. Clin Exp Rheumatol. 2024, 42:633-41. 10.55563\/clinexprheumatol\/3iqvk3","journal-title":"Clin Exp Rheumatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0588","article-title":"A call for gene expression analysis in whole blood of patients with rheumatoid arthritis (RA) as a biomarker for RA-associated interstitial lung disease","volume":"51","author":"Wierczeiko A","year":"2024","unstructured":"Wierczeiko A, Linke M, Friedrich JP, et al.. A call for gene expression analysis in whole blood of patients with rheumatoid arthritis (RA) as a biomarker for RA-associated interstitial lung disease. J Rheumatol. 2024, 51:130-3. 10.3899\/jrheum.2023-0588","journal-title":"J Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281177-a-systematic-review-on-biomarkers-are-there-reliable-molecular-biomarkers-in-patients-with-rheumatoid-arthritis-associated-interstitial-lung-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T09:10:29Z","timestamp":1723108229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281177-a-systematic-review-on-biomarkers-are-there-reliable-molecular-biomarkers-in-patients-with-rheumatoid-arthritis-associated-interstitial-lung-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.66422","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}